Switch theme
Sign up to access all valuation multiples
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
2018
35
LTM Revenue $0.5M
Last FY EBITDA -$54.9M
$186M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Compass Therapeutics has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Compass Therapeutics achieved revenue of $0.8M and an EBITDA of -$54.9M.
Compass Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Compass Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | $0.8M | XXX | XXX | XXX |
| Gross Profit | $0.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$54.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -6456% | XXX | XXX | XXX |
| EBIT | -$64.8M | XXX | -$56.6M | XXX | XXX | XXX |
| EBIT Margin | -12675% | XXX | -6662% | XXX | XXX | XXX |
| Net Profit | -$58.6M | XXX | -$49.4M | XXX | XXX | XXX |
| Net Margin | -11458% | XXX | -5809% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Compass Therapeutics's stock price is $2.
Compass Therapeutics has current market cap of $292M, and EV of $186M.
See Compass Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $186M | $292M | XXX | XXX | XXX | XXX | $-0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Compass Therapeutics has market cap of $292M and EV of $186M.
Compass Therapeutics's trades at 218.3x EV/Revenue multiple, and -3.4x EV/EBITDA.
Equity research analysts estimate Compass Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Compass Therapeutics has a P/E ratio of -5.0x.
See valuation multiples for Compass Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $292M | XXX | $292M | XXX | XXX | XXX |
| EV (current) | $186M | XXX | $186M | XXX | XXX | XXX |
| EV/Revenue | 362.8x | XXX | 218.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.4x | XXX | XXX | XXX |
| EV/EBIT | -2.9x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 362.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.0x | XXX | -5.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCompass Therapeutics's last 12 month revenue growth is 1885%
Compass Therapeutics's revenue per employee in the last FY averaged $24K, while opex per employee averaged $1.6M for the same period.
Compass Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Compass Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Compass Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1885% | XXX | 437% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -6456% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -4571% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $24K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4981% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6762% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Compass Therapeutics acquired XXX companies to date.
Last acquisition by Compass Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Compass Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Compass Therapeutics founded? | Compass Therapeutics was founded in 2018. |
| Where is Compass Therapeutics headquartered? | Compass Therapeutics is headquartered in United States of America. |
| How many employees does Compass Therapeutics have? | As of today, Compass Therapeutics has 35 employees. |
| Who is the CEO of Compass Therapeutics? | Compass Therapeutics's CEO is Dr. Thomas J. Schuetz, M.D.,PhD. |
| Is Compass Therapeutics publicy listed? | Yes, Compass Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Compass Therapeutics? | Compass Therapeutics trades under CMPX ticker. |
| When did Compass Therapeutics go public? | Compass Therapeutics went public in 2020. |
| Who are competitors of Compass Therapeutics? | Similar companies to Compass Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Compass Therapeutics? | Compass Therapeutics's current market cap is $292M |
| What is the current revenue of Compass Therapeutics? | Compass Therapeutics's last 12 months revenue is $0.5M. |
| What is the current revenue growth of Compass Therapeutics? | Compass Therapeutics revenue growth (NTM/LTM) is 1885%. |
| What is the current EV/Revenue multiple of Compass Therapeutics? | Current revenue multiple of Compass Therapeutics is 362.8x. |
| Is Compass Therapeutics profitable? | Yes, Compass Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
